BackTable / Urology / Contributor
Dr. Aditya Bagrodia
Genioturinary Oncologist
Dr. Aditya Bagrodia is an associate professor of urology and genitourinary oncology team leader at UC San Diego Health in California and adjunct professor of urology at UT Southwestern.
Listen to Dr. Aditya Bagrodia on the BackTable Urology Podcast
The BackTable Podcast is a knowledge resource by physicians for physicians. Learn from the experiences and expertise of Dr. Aditya Bagrodia and get practical advice on how to build your practice by listening to the BackTable Urology Podcast.
Stay Up To Date
Follow:
Subscribe:
Sign Up:
About Dr. Aditya Bagrodia
Aditya Bagrodia, M.D., is an associate professor of urology and genitourinary oncology team leader at UC San Diego Health in California and adjunct professor of urology at UT Southwestern.
Dr. Bagrodia holds a bachelor of science degree from Rhodes College. While earning a medical degree with highest honors at the University of Tennessee Health Sciences Center, he was awarded a Doris Duke Clinical Research Fellowship at UT Southwestern Medical Center.
After completing his residency in urology at UT Southwestern, he received advanced training in urologic oncology through a fellowship at Memorial Sloan Kettering Cancer Center, where he was awarded a Urology Care Foundation Research Scholars Grant by the American Urological Association.
Dr. Bagrodia’s clinical practice focuses on treating all urologic malignancies, including adrenal, upper tract, renal, bladder, prostate, penile, and testicular cancers. He has expertise in complex multidisciplinary management and minimally invasive approaches to urologic surgery.
Dr. Bagrodia has conducted extensive research in urologic oncology, primarily in biomarker profiles and molecular signatures of urologic tumors as predictors of clinical outcomes. He is funded through competitive grants from the Cancer Prevention and Research Institute of Texas (CPRIT), intramural research grants, and the National Institutes of Health.
Both his clinical practice and research centers on patients with germ cell tumors (most commonly testicular cancer). His laboratory focuses on sequencing efforts to understand tumor evolution and heterogeneity in germ cell tumors and identifying novel biomarkers to recognize occult metastatic disease. The Bagrodia lab also conducts experiments in cell lines, zebrafish germ cell tumor models, and mice to understand the biologic implications of genetic alterations that are seen exclusively among patients with cisplatin-resistance disease. He is actively working on molecular biomarkers to identify minimal residual disease burden. On the clinical side, Dr. Bagrodia is actively involved in understanding and overcoming unique socioepidemiologic considerations that adversely impact oncologic outcomes in patients with germ cell tumors. He is also the principal investigator for several germ cell tumor-directed clinical trials at UT Southwestern (including NCT03426865 and NCT02537548).
Dr. Bagrodia is the principal author or co-author of more than 100 articles in peer-reviewed publications such as Journal of Clinical Oncology, Nature Genetics, European Urology, Journal of Urology, Urologic Oncology, and Urology. He is also a reviewer for many of these publications, as well as for the British Journal of Urology, Journal of Clinical Pathology, and Annals of Surgical Oncology.
Learn more by visiting Dr. Aditya Bagrodia's practice:
Podcasts Featuring Dr. Aditya Bagrodia
Episode #204
Stay up to date in your bladder cancer practice with this insightful episode of the BackTable Urology podcast, developed in collaboration with the Society of Urologic Oncology. Dr. Betsy Koehne (University of Wisconsin) and Dr. Amir Salmasi (UC San Diego) talk through the contemporary management of low and intermediate-risk non-muscle-invasive bladder cancer.
Episode #203
Recent research is changing how we manage low risk prostate cancer. In this BackTable Urology Podcast episode, Dr. Dan Lin, a urologist at the University of Washington, walks through contemporary diagnosis, surveillance, and management of Grade Group 2 prostate cancer with host Dr. Aditya Bagrodia.
Episode #201
Retroperitoneal lymph node dissection (RPLND) for testicular cancer can be a challenging surgery, even for the most experienced urologic oncologists. In part one of this special two-part series, host Dr. Aditya Bagrodia invites Society of Urologic Oncologists (SUO) members Dr. Timothy Masterson (Indiana University) and Dr. Robert Hamilton (Princess Margaret Hospital/University of Toronto) to cover current approaches to post-chemotherapy RPLND.
Episode #200
Biochemical recurrence of prostate cancer can be difficult to diagnose and treat. In this episode of BackTable Urology, where Dr. Aditya Bagrodia hosts Dr. Amar Kishan, a genitourinary radiation oncologist at UCLA, to discuss the complexities of biochemical recurrence and local failure after radiation therapy for prostate cancer.
Episode #197
Frustrated with stone retrieval after a long lithotripsy case? In this episode of the BackTable Urology Podcast, host Aditya Bagrodia, MD, and guest Roger Sur, MD, director of the Comprehensive Kidney Stone Center at UC San Diego Health, delve into the latest technological advancements in the treatment of kidney stones. The episode focuses on the CVAC (continuous vacuum aspiration and irrigation) device as a suction platform for endourologists.
Episode #189
Did you know that robotic prostatectomy has its roots in both the immigrant experience and the renowned manufacturing legacy of Detroit? In this episode of BackTable Urology, Dr. Mani Menon, a pioneer in robotic surgery, joins Dr. Aditya Bagrodia to discuss the development of robotic prostatectomy technology.
Episode #181
It can be tough to avoid burnout, stay motivated, and retain your passion for patient care when facing the day-to-day challenges of medical practice. In this episode of the BackTable Urology Podcast, Dr. Alexander Kutikov from Fox Chase Cancer Center discusses keys to developing a sustainable and fulfilling career within urology.
Episode #170
In this episode of BackTable Urology, host Dr. Aditya Bagrodia, urologic oncologist Dr. Philippe Speiss (Moffitt Cancer Center), and medical oncologist Dr. Andrea Necchi (Università Vita-Salute San Raffaele) have an in-depth discussion about the mission and achievements of the Global Society of Rare Genitourinary Tumors (GSRGT).
Articles Featuring Dr. Aditya Bagrodia
Compared to resection or radiation, focal therapy may offer a less invasive and more precise treatment option for prostate cancer patients. Who is the ideal patient for prostate cancer focal therapy? Which focal therapy modality is best? How do we optimize care after focal therapy to ensure that recurrence is managed effectively?
Advancements in genomics and imaging are transforming prostate cancer diagnosis and treatment by reducing overdiagnosis and personalizing treatment. Learn more about the integration of genomic tests and imaging techniques to help distinguish between benign conditions and clinically significant cancers.
Radical therapy remains the cornerstone in the treatment of high-risk prostate cancer, encompassing modalities such as radical prostatectomy and brachytherapy. Criteria for the high-risk prostate cancer designation typically include a Gleason score ranging from 8 to 10, grade 4 or 5, or PSA levels surpassing 20.
BCG-unresponsive bladder cancer has distinct criteria for diagnosis and management. Official FDA diagnosis requires the development or recurrence of a high-grade bladder tumor after a patient has received adequate BCG therapy. Treatment duration varies based on whether an induction or maintenance course is indicated.
Get Connected
Thank you for listening! If you have a question for Dr. Aditya Bagrodia about a topic discussed on the BackTable Urology Podcast, you can get in touch with this form. Please note that our contributors are not able to respond to every inquiry.
Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.